The GABAB receptor antagonist CGP 36,742 and the nootropic oxiracetam facilitate the formation of long-term memory.
The memory-enhancing effects of a single treatment with the GABAB antagonist CGP 36,742 (10 mg/kg) or the nootropic agent oxiracetam (100 mg/kg) given immediately after a learning experience ('post-trial') remain detectable for at least 4 months thereafter. This indicates that in all probability these substances facilitate the formation of the long-term memory trace.
Mondadori
C
C
Pharmaceutical Research Department, CIBA Ltd., Basel, Switzerland. cesaremondadori@mmd.com
Möbius
H J
HJ
Borkowski
J
J
D000818:Animals; D001921:Brain / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D018756:GABA Antagonists / Q000494:pharmacology*; D017774:Long-Term Potentiation / Q000187:drug effects*; D011939:Mental Recall / Q000187:drug effects*; D051379:Mice; D008815:Mice, Inbred Strains; D018697:Nootropic Agents / Q000494:pharmacology*; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D011759:Pyrrolidines / Q000494:pharmacology*; D018080:Receptors, GABA-B / Q000187:drug effects*
D018756:GABA Antagonists; D018697:Nootropic Agents; D009943:Organophosphorus Compounds; D011759:Pyrrolidines; D018080:Receptors, GABA-B; C079148:(3-aminopropyl)(n-butyl)phosphinic acid; C040619:oxiracetam